AQEMIA funding news – Paris-based AQEMIA has Raised €94.9 Million in Funding

The latest round was led by Cathay Innovation, with support from previous investors like Wendel, Bpifrance Large Venture, Eurazeo, and Elaia.

This funding includes €30 million raised in 2022 and a recent €36 million round. The new funding comes after successful results from AQEMIA’s drug discovery platform, particularly in oncology, and positive partnerships with pharmaceutical companies.

With this funding, It is moving closer to clinical trials and expanding globally, starting with a new office in London.

Read also - Alstin Capital funding news – Munich-based Alstin Capital has Secured €175 Million in Funding

Maximilien Levesque, PhD, CEO and co-founder of AQEMIA said, “This is a transformative moment for AQEMIA, Less than a year after our last round, this successful fundraising and the opening of our new London office mark significant strides toward our ambition to accelerate the discovery of new medicines on a global scale. Partnering with Cathay Innovation brings international expertise, particularly in the US and Asia, reinforcing our vision and mission. With this momentum, we are poised to advance to clinical trials, bringing us closer to delivering life-changing treatments to patients in need.”

AQEMIA uses technology to create new, safe small-molecule drugs without needing experimental data. Instead, it trains AI using principles from theoretical physics, allowing it to design new molecules that go beyond existing drugs.

The company has recently seen success in oncology, including positive results and a €132.9 million partnership with Sanofi, showing strong progress.

Purpose of fund raising

The new funding will help it to prepare for clinical trials and further improve its innovative drug discovery platform. Their method removes the need for experimental data, solving a key challenge in AI by creating unique molecular solutions that are not based on existing compounds.

It will open a new office in London’s King’s Cross area in January 2025. This office will strengthen its presence in the UK and help the company access talent in life sciences and techbio. It is an important step in AQEMIA’s global growth and its goal to lead in AI-driven drug discovery.

Jacky Abitbol, partner at Cathay Innovation said, “We have long been committed to supporting visionary entrepreneurs who harness the transformative potential of AI to reshape the healthcare industry, AQEMIA embodies the future of drug discovery, combining the power of AI with quantum mechanics. Fueled by Maximilien and Emmanuelle the company’s vision is one that is fully aligned with Cathay Innovation’s DNA, as it aims to profoundly transform the molecule research and pharmaceutical industry as a whole. Our partnership goes beyond capital support; we are putting to good use our experience in scaling AI-driven companies all over the world, particularly across US and Asia, as AQEMIA accelerates its path to the clinic and expands its global impact.“

About AQEMIA

AQEMIA is a modern pharmatech company creating one of the fastest-growing drug discovery pipelines in the world. Our goal is to quickly design innovative drug candidates for many serious diseases, including immuno-oncology.